IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9957219 B1

PDFFull Text
Date of Patent:
May. 01, 2018

Filed:

Dec. 01, 2014

Antidiabetic bicyclic compounds

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Thomas Bara, Scotch Plains, NJ (US);

Harry R. Chobanian, Aberdeen, NJ (US);

Yan Guo, Westfield, NJ (US);

Hubert Josien, Jersey City, NJ (US);

Michael Miller, Scotch Plains, NJ (US);

Barbara Pio, West Orange, NJ (US);

Christopher W. Plummer, Hoboken, NJ (US);

Cangming Yang, South River, NJ (US);

Dong Xiao, Warren, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Baerbel R. Brown

Catherine D. Fitch

Primary Examiner:

Sudhakar Katakam

Int. Cl.
CPC ...
C07C 59/72 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/404 (2006.01); A61K 31/435 (2006.01); C07D 221/04 (2006.01); C07D 231/12 (2006.01); C07D 207/333 (2006.01); C07D 277/42 (2006.01); C07D 209/12 (2006.01); A61K 31/277 (2006.01); A61K 31/381 (2006.01); A61K 31/415 (2006.01); A61K 31/4192 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); C07C 255/59 (2006.01); C07D 209/08 (2006.01); C07D 213/64 (2006.01); C07D 249/04 (2006.01); C07D 333/24 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07C 59/72 (2013.01); A61K 31/192 (2013.01); A61K 31/277 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/4192 (2013.01); A61K 31/427 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 45/06 (2013.01); C07C 255/59 (2013.01); C07D 207/333 (2013.01); C07D 209/08 (2013.01); C07D 209/12 (2013.01); C07D 213/64 (2013.01); C07D 221/04 (2013.01); C07D 231/12 (2013.01); C07D 249/04 (2013.01); C07D 277/42 (2013.01); C07D 333/24 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07C 2601/02 (2017.05); C07C 2601/14 (2017.05); C07C 2602/06 (2017.05); C07C 2602/08 (2017.05);
Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Find Patent Forward Citations

Loading…